XALUPRINE

This brand name is authorized in Austria, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug XALUPRINE contains one active pharmaceutical ingredient (API):

1	Mercaptopurine monohydrate UNII E7WED276I5 - MERCAPTOPURINE
	Mercaptopurine is an inactive pro-drug which acts as a purine antagonist but requires cellular uptake and intracellular anabolism to thioguanine nucleotides for cytotoxicity. The mercaptopurine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions. The thioguanine nucleotides are also incorporated into nucleic acids and this contributes to the cytotoxic effects of the active substance.
	Read more about Mercaptopurine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XALUPRINE Oral suspension	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BB02	Mercaptopurine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues
Discover more medicines within L01BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1558920
FI	Lääkealan turvallisuus- ja kehittämiskeskus	164324
FR	Base de données publique des médicaments	63798857
GB	Medicines & Healthcare Products Regulatory Agency	219703
IE	Health Products Regulatory Authority	43350
IT	Agenzia del Farmaco	044665014
LT	Valstybinė vaistų kontrolės tarnyba	1065399
NL	Z-Index G-Standaard, PRK	103748
PL	Rejestru Produktów Leczniczych	100313569